IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17 inhibitors are starting to be prescribed in earlier lines of therapy, the biologics market is still dominated by TNF-α inhibitors and Stelara. Nonetheless, emerging therapies may find opportunities to address the unmet needs in the moderate to severe psoriasis market identified in this report.
- What are the treatment drivers and goals for psoriasis?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?
- What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new moderate to severe psoriasis drug?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European dermatologists fielded in January and February 2018.
Key companies: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis.
Key drugs: Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz, Tremfya.